SGLT-2 inhibitors reduce adverse CV events associated with restenosis in stents in patients with type 2 diabetes.

Published Date: 13 Mar 2023

Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy

2.

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

3.

CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group

4.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

5.

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot